We plan to achieve over 25% annual growth in API business: Ashok Nair, MD, RPG Life Sciences

RPG Life Sciences is scaling its active pharmaceutical ingredients (API) business, as it aims to clock over 25 per cent growth on the back of increased manufacturing capacity and bolster its backward integration and its international footprint in regulated markets.
The new RPG Active Pharma platform launched by the company will help it gain a focused approach towards its API business, with all aspects of capital investment, acquisition, manufacturing growth, and R&D being put together under one business platform.
RPG Life Sciences’ Managing Director, Ashok Nair, added that the establishment of RPG Active Pharma will allow the firm to be more aggressive in exploiting opportunities available compared to the previous organisational setup of the firm.
“We have gone from one API plant to three plants, almost five times the manufacturing capacity, and almost double the customer base, whilst expanding our product and R&D pipeline, all within a relatively short span of time,” he told ET Manufacturing.
The company has invested ₹700 crore to build the organisation, with investments being made in phases. The initial phase of investment involved the acquisition of companies Actis and Raghava, whereas the future investments will go into select acquisitions, capacity debottlenecking, regulatory improvements, and backward integration.
However, according to Nair, the firm will concentrate more on the yields from the investments rather than the capital itself. “Our plan is to grow the API business significantly, achieving more than 25 per cent growth per year, increasing exports, improved utilisation of assets and good yields on capital,” he said.
Acquisitions for improving chemistry and backward integration
One of the major aspects of RPG Active Pharma's growth plan includes adding competencies which otherwise might have taken time to build if done organically.
By acquiring Actis Generics, the company significantly improved its capabilities in context to complex intermediates and multi-step chemistry, apart from the facilities for manufacturing, technical talent, and a customer base.
As per Nair, the deal has provided the opportunity for increased backward integration, with intermediates made by Actis being used in the manufacture of APIs. This is likely to provide a cost advantage, as well as increase supply security and fast entry into the market.
The firm is currently in the process of integrating Actis into its business processes, and their immediate priorities involve issues like customer continuity, talent retention, quality and systems integration, and capacity debottlenecking.
As far as the bigger picture is concerned, the integration of Actis’ intermediate manufacturing facilities with those of Raghava at its API unit in Navi Mumbai presents greater opportunities.
Moreover, RPG Active Pharma is also trying to cut down its reliance on single sources, especially from China, by creating quality and competitive sources in India.
As Nair puts it, the skill set acquired from Actis and Raghava will assist RPG Active Pharma in building up its competence in intermediates and multi-step chemistry, assisting with both supply-chain resilience and manufacturing economics.


